Mp80-19 robot-assisted radical prostatectomy for prostate cancer: 18-year oncological outcomes from a belgian high-volume center

You have accessJournal of UrologyCME1 Apr 2023MP80-19 ROBOT-ASSISTED RADICAL PROSTATECTOMY FOR PROSTATE CANCER: 18-YEAR ONCOLOGICAL OUTCOMES FROM A BELGIAN HIGH-VOLUME CENTER Luigi Nocera, Carlo Bravi, Marco Paciotti, Adele Piro, Eleonora Balestrazzi, Maria Peraire Lores, Federico Piramide, Angelo Mottaran, Luca Sarchi, Rui Farinha, Frederiek D'Hondt, Geert De Naeyer, Ruben De Groote, and Alexandre Mottrie Luigi NoceraLuigi Nocera More articles by this author , Carlo BraviCarlo Bravi More articles by this author , Marco PaciottiMarco Paciotti More articles by this author , Adele PiroAdele Piro More articles by this author , Eleonora BalestrazziEleonora Balestrazzi More articles by this author , Maria Peraire LoresMaria Peraire Lores More articles by this author , Federico PiramideFederico Piramide More articles by this author , Angelo MottaranAngelo Mottaran More articles by this author , Luca SarchiLuca Sarchi More articles by this author , Rui FarinhaRui Farinha More articles by this author , Frederiek D'HondtFrederiek D'Hondt More articles by this author , Geert De NaeyerGeert De Naeyer More articles by this author , Ruben De GrooteRuben De Groote More articles by this author , and Alexandre MottrieAlexandre Mottrie More articles by this author View All Author Informationhttps://doi.org/10.1097/JU.0000000000003357.19AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: Since its introduction in the treatment landscape of prostate cancer (PCa), robot-assisted radical prostatectomy (RARP) exhibited excellent short- and mid-term oncological outcomes. However, long-term oncological outcomes are still underreported. Here, we examined oncological outcomes of a single-center RARP cohort with the longest follow-up. METHODS: We retrospectively identified 2,451 PCa patients treated with RARP at a high-volume tertiary referral center between 2002 and 2020. Kaplan-Meier (KM) analyses examined biochemical recurrence (BCR), clinical recurrence (CR) and cancer-specific mortality (CSM) rates. Uni- and multi-variable Cox regression models assessed independent predictors of BCR, CR and CSM after stratification for age, year of surgery (YOS) and PSA level. RESULTS: Median (interquartile range [IQR]) age and preoperative PSA were 64 (59, 69) years and 7.3 (5.3, 10.6) ng/ml. Most patients harbored a cT1c disease (45%), followed by cT2a, cT2c, cT3, cT2b and cT1a-b, accounting for 21%, 17%, 10%, 5% and 2%, respectively. The vast majority of patients had biopsy ISUP group 1-2 (78%), followed by ISUP group 3 and 4-5 in 12% and 11%. On final pathology, most patients harbored pT2 disease (66%), followed by pT3a (20%), pT3b (6%) and pT4 (<1%) disease, whereas ISUP group 1-2 was the most frequent grade (69%), followed by ISUP group 3 and 4-5 in 21% and 11% of patients. pN1 disease was found in 7% of patients. A total of 425 (17%) patients had PSM. During follow-up, 584 patients experienced BCR, 286 CR and 41 CSM. The 15-year BCR-, CR- and CSM-free survival was 64% (95% confidence interval [CI]: 62%, 67%), 78% (95%CI: 75%, 81%) and 95% (95%CI: 92%, 97%) respectively (Figure 1). The 18-year BCR-, CR- and CSM-free survival was 64% (95%CI: 61%, 67%), 75% (95%CI: 71%, 79%) and 95% (95%CI: 92%, 97%) respectively. On multivariable Cox regression model, pathological stage, pathological ISUP grade group and PSM represented all independent predictors of BCR, CR and CSM (all p<0.01). CONCLUSIONS: Our study – with the longest follow-up in a series of RARPs – showed excellent oncological outcomes after surgery in individuals with favorable PCa characteristics, also after 18 years of follow-up. Further, multi-center validations are awaited to confirm these findings. Source of Funding: None © 2023 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 209Issue Supplement 4April 2023Page: e1160 Advertisement Copyright & Permissions© 2023 by American Urological Association Education and Research, Inc.MetricsAuthor Information Luigi Nocera More articles by this author Carlo Bravi More articles by this author Marco Paciotti More articles by this author Adele Piro More articles by this author Eleonora Balestrazzi More articles by this author Maria Peraire Lores More articles by this author Federico Piramide More articles by this author Angelo Mottaran More articles by this author Luca Sarchi More articles by this author Rui Farinha More articles by this author Frederiek D'Hondt More articles by this author Geert De Naeyer More articles by this author Ruben De Groote More articles by this author Alexandre Mottrie More articles by this author Expand All Advertisement PDF downloadLoading ...